Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, saying the evidence backing the drug isn’t strong enough.

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

And more. 1. AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial AstraZeneca and Daiichi Sankyo reported a positive readout for Enhertu as a neoadjuvant therapy ...

Among Japanese drugmakers, many of which generate significant parts of their revenue in the U.S., share of Daiichi Sankyo were recently ... analysis is clear and in no way misleading or deceptive.

It’s not like he came out and was like, ‘Hey, I’m Pope Leo XIV, he/him.’ The reality is there are no woke Catholics. If you’re a woke Catholic, you’re just not a Catholic anymore.” ...

We're sorry, but something went wrong while fetching your podcast feeds. Please contact us at plus@slate.com for help. Despite being perhaps the least experienced ...

EXCLUSIVE: French director Vincent Maël Cardona makes his Cannes Official Selection debut with huis-clos thriller No One Will Know, which premieres as a Midnight Screening. The drama revolves ...

The Utah Hockey Club is no more. After an exhaustive search that ... and the unstoppable force we’re building together.” The main logo for the franchise will be the “Mountain Mammoth ...